Event-Driven Stocks

Entrada Therapeutics, Inc.

TRDANasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$25.4M$210.8M$129.0M———
Operating income−$157.9M$47.0M−$3.2M−$97.2M−$51.1M−$26.7M
Net income−$143.8M$65.6M−$6.7M−$94.6M−$51.2M−$26.5M
Total assets$377.4M$526.3M$469.2M$252.1M$305.8M$43.5M
Total liabilities$71.2M$97.6M$226.8M$39.5M$7.1M$3.4M
Equity$306.1M$428.7M$242.4M$212.6M$298.7M−$41.5M
EPS (diluted)$-3.47$1.68$-0.20$-3.02$-8.16$-24.00
Shares out.37.6M33.6M33.1M31.3M31.2M1.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−621.1%
Net margin
−565.5%
Return on equity
−47.0%
Return on assets
−38.1%
Return on capital (ROCE)
−44.7%
Liabilities / assets
18.9%
Debt / equity
0.23×
Book value / share
$8.14
Revenue growth (YoY)
−87.9%
Net income growth (YoY)
−319.0%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
4.24safe
Accruals / assets
−4.0%clean
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
47
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 4 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.5M1.6+51.0%
Apr 30, 2026998,3525.5+17.1%
Apr 15, 2026852,2475.5-4.7%
Mar 31, 2026894,1524.7-3.3%
Mar 13, 2026924,2653.5+12.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.